Yamaguchi Syndrome (Apical Hypertrophic Cardiomyopathy)
Diagnosis
Yamaguchi syndrome should be diagnosed using cardiac magnetic resonance (CMR) imaging as the gold standard, combined with characteristic ECG findings of giant negative T-waves (>10 mm) in precordial leads V4-V6 and transthoracic echocardiography showing apical left ventricular wall thickness ≥15 mm with the pathognomonic "ace-of-spades" cavity configuration 1, 2.
Diagnostic Algorithm
Step 1: ECG Recognition
- Look for giant T-wave inversions (>10 mm) in precordial leads, particularly V4-V6
- These changes frequently mimic acute coronary syndrome 2, 3, 4
- ST-segment depression may also be present
Step 2: Initial Imaging with Echocardiography
- Transthoracic echocardiography is first-line but has significant limitations due to poor apical visualization 1
- Use contrast-enhanced echocardiography to improve diagnostic accuracy - this is critical as standard TTE often misses the diagnosis 1
- Measure apical wall thickness (diagnostic threshold ≥15 mm in adults, or 13-14 mm with positive family history) 5
- Identify the characteristic "ace-of-spades" or "spade-like" left ventricular cavity configuration 3, 6
- Assess Global Longitudinal Strain (GLS) - typically reduced (e.g., -14.3% to -15.8%) 2, 7
Step 3: Definitive Diagnosis with CMR
- CMR is mandatory for definitive diagnosis and risk stratification 1, 2
- CMR provides superior visualization of apical hypertrophy that echocardiography commonly misses 1, 6
- Quantify late gadolinium enhancement (LGE) to assess myocardial fibrosis burden - this is essential for sudden cardiac death risk stratification 1, 2
- Detect apical aneurysms, which significantly increase risk 1
Step 4: Exclude Coronary Disease
- Coronary computed tomography angiography (CCTA) or invasive angiography is necessary because the presentation mimics ACS 2, 3, 4
- Despite ischemic symptoms and ECG changes, coronary arteries are typically normal 2, 3
- Serial high-sensitivity troponin should remain normal or minimally elevated 2
Critical Diagnostic Pitfall
The most common error is misdiagnosing Yamaguchi syndrome as acute coronary syndrome and performing unnecessary invasive procedures 3, 4. The giant T-wave inversions create a Wellens-like pattern that mimics critical LAD disease 4. Always consider ApHCM when ECG shows giant T-wave inversions but troponins are normal.
Management
Medical Therapy for Symptomatic Patients
For symptomatic patients with chest pain or dyspnea, initiate beta-blockers as first-line therapy, with non-dihydropyridine calcium channel blockers (verapamil or diltiazem) as alternatives 8, 9.
Specific medication approach:
- Beta-blockers (e.g., metoprolol, bisoprolol) are the primary therapy 8, 2, 4
- Non-dihydropyridine calcium channel blockers (verapamil >6 months age, or diltiazem) reduce chest pain and improve exercise capacity 8
- Titrate doses to effectiveness while monitoring for bradycardia or AV block, especially if combining agents 8
Additional pharmacotherapy:
- Angiotensin receptor blockers (e.g., losartan, telmisartan) can be added safely without adverse consequences, though evidence for symptom benefit is limited 8, 2, 4
- Trimetazidine may provide additional symptomatic relief 2
- Diuretics (loop or thiazide) should be used cautiously and intermittently for volume overload, as aggressive diuresis can cause symptomatic hypotension in these patients with small LV cavities 8
Critical medication warnings:
- Avoid peripheral vasodilators and PDE5 inhibitors - these can worsen symptoms 10
- Avoid dihydropyridine calcium channel blockers 8
- Prevent dehydration and excess alcohol intake 10
Surgical Intervention for Refractory Cases
For highly selected patients with severe refractory symptoms (NYHA class III-IV) despite maximal medical therapy who have a small LV cavity (end-diastolic volume <50 mL/m² and stroke volume <30 mL/m²), transapical myectomy at a comprehensive HCM center of excellence may be considered 8, 9.
This surgical approach:
- Augments LV cavity size to increase stroke volume and decrease LV end-diastolic pressure 8
- Requires extensive surgical experience and should be limited to highest-volume centers 8
- Has been shown to be safe and reduce symptoms in this rare subgroup 8
Sudden Cardiac Death Risk Stratification
All patients require comprehensive sudden cardiac death risk assessment using the 2024 AHA/ACC risk calculator, with particular attention to CMR-derived markers 5, 1.
High-risk features requiring ICD consideration:
- Extensive myocardial fibrosis on CMR (quantified by LGE burden) 1, 2, 6
- Presence of apical aneurysm 1
- History of cardiac arrest or sustained ventricular arrhythmias 6, 7
- Non-sustained ventricular tachycardia on monitoring 6
An ICD was required in documented high-risk cases with extensive fibrosis 6.
Atrial Fibrillation Management
If atrial fibrillation develops, anticoagulation is mandatory regardless of CHA₂DS₂-VASc score, using direct oral anticoagulants as first-line 9.
Lifestyle Modifications
Patients must avoid competitive sports and strenuous physical activity 10. However, low to moderate aerobic recreational activity is permitted based on individual risk assessment 10.
Dietary considerations:
- Smaller, more frequent meals rather than large meals (which can precipitate chest pain) 10
- Maintain healthy body mass index 10
- Manage constipation if on verapamil/disopyramide 10
Follow-up and Monitoring
- Regular clinical follow-up at specialized HCM centers
- Periodic rhythm monitoring to detect subclinical atrial fibrillation 9
- Family screening with ECG and echocardiography (autosomal dominant inheritance with 50% transmission risk) 10
- Genetic counseling for patients and relatives 10
Asymptomatic Patients
For asymptomatic patients, there is no established benefit of beta-blockers or calcium channel blockers, and these agents may paradoxically cause chronotropic incompetence 8. Focus on risk stratification, lifestyle modification, and surveillance rather than empiric medical therapy.